About | What We Do
APT Pharmaceuticals is focused on the development of cyclosporine inhalation solution (CIS) for the prevention and treatment of chronic rejection in lung transplantation. The company has successfully enrolled a large, multi-center Phase III clinical trial evaluating the effect of CIS on chronic rejection. APT is preparing for study data and commercialization of the product in the US and Europe. The company has an experienced management team and has partnered with leaders in the field of life sciences investing.
CIS holds significant promise primarily because:
- It has the potential to provide clinical benefit in an area of significant unmet medical need
- APT expects a positive outcome from the Phase III trial. Data from nine clinical studies with cyclosporine inhalation solution provide supporting evidence for the drug’s potential clinical utility
- There are no approved drugs or products in late stage development to prevent chronic rejection in lung transplantation
- Lung transplantation is a niche market that can be well served by a small, focused company
APT has raised the money required to complete the Phase III trial and seek regulatory approval.